文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19患者呼吸机相关性肺炎的流行病学与微生物学:法国未受疫情淹没地区188例患者的多中心回顾性研究

Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region.
PubMed 文献 · Crit Care · 2021-02-18
一句话结论重症COVID-19有创通气患者VAP发生率高达39.0例/1000通气日,肠杆菌占病原49.8%,男性VAP风险更高(sHR 2.24)。

本研究回顾性收集法国Pays-de-Loire地区7个ICU第一波疫情期间因COVID-19住院且有创机械通气超过48小时的患者资料,VAP依据官方推荐诊断且仅纳入定量微生物培养确认的病例,共分析188例患者。结果显示48.9%发生VAP,19.7%经历多次发作;至首次VAP发作的发病率为39.0例/1000通气日,包含全部141次VAP发作的发病率为33.7例/1000通气日。多微生物VAP占39.0%,共鉴定205株病原体,肠杆菌占分离病原体的49.8%;15例(10.6%)VAP合并菌血症,5例(3.5%)并发脓胸,2例(1.4%)并发肺脓肿。男性VAP风险更高(sHR 2.24,95%CI 1.18–4.26,p=0.013)。作者认为,即使ICU未受疫情淹没,重症COVID-19患者的VAP发生率仍异常之高,肠杆菌占相当比例,VAP相关并发症(脓肿、脓胸)并不罕见。

要点

  • 188例COVID-19有创通气>48小时患者中48.9%发生VAP,19.7%经历多次发作,至首次VAP的发病率为39.0例/1000通气日。
  • 包含全部141次VAP发作的发病率为33.7例/1000通气日。
  • 多微生物VAP占39.0%,共鉴定205株病原体,肠杆菌占分离病原体的49.8%。
  • 15例(10.6%)VAP合并菌血症,5例(3.5%)并发脓胸,2例(1.4%)并发肺脓肿。
  • 男性与更高的VAP风险相关(sHR 2.24,95%CI 1.18–4.26,p=0.013)。

适用人群与场景

  • 法国Pays-de-Loire地区7个ICU中第一波疫情期间因COVID-19住院、有创机械通气超过48小时的全部患者。

诊断标准与关键阈值

  • VAP依据官方推荐诊断,且仅纳入经定量微生物培养确认的VAP病例。

研究设计与关键结果

  • 多中心回顾性研究,纳入188例COVID-19有创机械通气>48小时患者,分析VAP特征。
  • 48.9%发生VAP,19.7%经历多次VAP发作。
  • 至首次VAP发作的发病率为39.0例/1000通气日;包含全部141次VAP发作的发病率为33.7例/1000通气日。
  • 多微生物VAP占全部VAP的39.0%,共鉴定205株病原体,肠杆菌占分离病原体的49.8%。
  • 15例(10.6%)VAP合并菌血症,5例(3.5%)并发脓胸,2例(1.4%)并发肺脓肿。
  • 男性VAP风险更高(sHR 2.24,95%CI 1.18–4.26,p=0.013)。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究(7个ICU)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,即使ICU未受疫情淹没,重症COVID-19有创通气患者的VAP发生率仍异常之高,应关注VAP的预防与识别。
  • 作者指出,肠杆菌在分离病原体中占相当比例(49.8%),VAP相关并发症(脓肿、脓胸)并不罕见。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The COVID-19 pandemic is responsible for many hospitalizations in intensive care units (ICU), with widespread use of invasive mechanical ventilation (IMV) which exposes patients to the risk of ventilator-associated pneumonia (VAP). The characteristics of VAP in COVID-19 patients remain unclear.

METHODS: We retrospectively collected data on all patients hospitalized for COVID-19 during the first phase of the epidemic in one of the seven ICUs of the Pays-de-Loire region (North-West France) and who were on invasive mechanical ventilation for more than 48 h. We studied the characteristics of VAP in these patients. VAP was diagnosed based on official recommendations, and we included only cases of VAP that were confirmed by a quantitative microbiological culture.

FINDINGS: We analyzed data from 188 patients. Of these patients, 48.9% had VAP and 19.7% experienced multiple episodes. Our study showed an incidence of 39.0 VAP per 1000 days of IMV (until the first VAP episode) and an incidence of 33.7 VAP per 1000 days of IMV (including all 141 episodes of VAP). Multi-microbial VAP accounted for 39.0% of all VAP, and 205 pathogens were identified. Enterobacteria accounted for 49.8% of all the isolated pathogens. Bacteremia was associated in 15 (10.6%) cases of VAP. Pneumonia was complicated by thoracic empyema in five cases (3.5%) and by pulmonary abscess in two cases (1.4%). Males were associated with a higher risk of VAP (sHR 2.24 CI95% [1.18; 4.26] p = 0.013).

INTERPRETATION: Our study showed an unusually high incidence of VAP in patients admitted to the ICU for severe COVID-19, even though our services were not inundated during the first wave of the epidemic. We also noted a significant proportion of enterobacteria. VAP-associated complications (abscess, empyema) were not exceptional.

REGISTRATION: As an observational study, this study has not been registered.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Blonz G, Kouatchet A, Chudeau N, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021. PMID: 33602296. doi:10.1186/s13054-021-03493-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。